Pulmonx Corporation LUNG

LUNG Company Overview

Pulmonx Corporation is a U.S.-based medical technology company focused on minimally invasive treatments for severe lung disease, primarily emphysema associated with chronic obstructive pulmonary disease (COPD). The company operates within the interventional pulmonology and respiratory medical device industries and is best known for its Zephyr Endobronchial Valve system, a bronchoscopic treatment designed to reduce hyperinflation in patients with severe emphysema. Pulmonx generates most of its revenue from the sale of its valve systems, related catheter products, and procedural support services used by hospitals and specialized pulmonary care centers.

The company’s core customer base includes pulmonologists, thoracic specialists, and healthcare systems treating advanced COPD patients. Pulmonx has positioned itself as a leader in bronchoscopic lung volume reduction (BLVR), supported by clinical trial data, regulatory approvals in multiple regions, and physician training infrastructure. Founded in 1995, the company evolved from an early-stage pulmonary device developer into a publicly traded respiratory intervention company following years of clinical development, commercialization expansion, and regulatory milestones, including U.S. FDA approval for the Zephyr Valve in 2018.